If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
102
results.
Updated on
20/08/2026 [07:13:00]
Results 75 to 100 of 102
Absstract of: WO2026138823A1
Provided are a coronavirus-targeting broad-spectrum binding-blocking protein and a use thereof. Specifically, provided is a novel coronavirus Spike protein (S protein)-targeting binding protein having ultra-high affinity, wherein the protein can bind to an RBD area of the S protein and can block binding of a novel coronavirus to an ACE2 receptor, thereby blocking the novel coronavirus from invading host cells. Also provided is a novel coronavirus S protein-targeting self-assembling trimeric protein having high affinity, wherein the protein exhibits broad-spectrum blocking protection activity against novel coronaviruses.
Absstract of: US20260183383A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.
Absstract of: US20260183407A1
0000 The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLKI, CLK2, CLK3, CLK4, and HASPIN. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, and HASPIN, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer), a viral infection (e.g., SARS-COV-2 infection (e.g., COVID-19)), and other diseases.
Absstract of: WO2026142889A1
Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory -based disease and disorders comprising administration of ImmunoFolate.
Absstract of: US20260185108A1
0000 Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.
Absstract of: KR20260101878A
본 발명은 황기 및 단삼 혼합 추출물을 유효성분으로 포함하는 만성 코로나19 증후군의 예방, 개선 또는 치료용 조성물에 관한 것으로, 코로나 바이러스 감염 후 브레인포그(brain fog)를 나타내는 환자가 본 발명의 황기 및 단삼 혼합 추출물을 복용한 후, 동기부여 능력, 집중력, 기억력 및 브레인포그 VAS(Visual Analog Scale) 상태 변화가 통계적으로 유의미하게 개선된 효과가 있으며, 현저하게 저하된 혈중 코티졸 수치가 증가되는 효과가 우수하므로, 만성 코로나19 증후군의 예방 및 치료용 의약품 또는 만성 코로나19 증후군 예방 및 개선용 건강기능식품으로 유용하게 사용될 수 있다.
Absstract of: WO2025137284A2
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.
Absstract of: CN122302045A
The invention provides a humanized antibody with neutralizing capacity for a new coronavirus JN.1 variant and application of the humanized antibody, and belongs to the technical field of biological medicine, the antibody comprises a heavy chain sequence as shown in SEQ ID NO: 1 and a light chain sequence as shown in SEQ ID NO: 2; or comprises a heavy chain sequence as shown in SEQ ID NO: 3 and a light chain sequence as shown in SEQ ID NO: 4. The binding EC50 value of the antibody and a JN.1 variant spike protein extracellular domain is obviously lower than that of a parent antibody, and the binding capacity is improved by 3-5 times or above. In a pseudovirus neutralization experiment, the half neutralization concentration (IC50) of the antibody to JN.1 pseudovirus is also remarkably superior to that of a parent antibody, and the neutralization activity is improved by 3-24 times or more. In addition, the melting temperature of the antibody exceeds 75 DEG C, and the antibody shows good thermal stability.
Absstract of: CN122278873A
The invention discloses a rice codon optimized SARS-CoV-2 Ommitron flannel variant receptor binding domain dimer protein gene and an application of the rice codon optimized SARS-CoV-2 Ommitron flannel variant receptor binding domain dimer protein gene. The OdiRBD gene is formed by connecting two segments of RBD sequences through a flexible peptide. The method comprises the following steps: crushing transgenic rice, mixing the crushed transgenic rice with an extraction buffer solution, carrying out ultrasonic splitting decomposition, and further extracting and filtering to obtain a crude extract containing OdiRBD; and carrying out nickel column chromatography on the crude extract containing the OdiRBD, so as to obtain the purified OdiRBD. The plant obtained by the method is stable in expression, high in extraction efficiency and suitable for large-scale production. The rice source OdiRBD purified by the method can effectively induce body fluid, mucous membrane and cellular immune response in a mouse body through intranasal immunization, can be used for developing mucous membrane vaccines expressed by rice, and has a good application prospect.
Absstract of: CN122277481A
The invention discloses a small molecule compound based on an acylthiourea skeleton or a derivative of the small molecule compound and application of the small molecule compound to anti-coronavirus, and relates to the technical field of anti-coronavirus drugs. The acylthiourea small molecule compound with the same structural general formula is provided for different kinds of coronaviruses, has a good inhibition effect on the activity of various kinds of coronaviruses, can be developed as a novel anti-coronavirus drug, and has a wide application prospect.
Absstract of: CN122277534A
The present invention provides, inter alia, compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. The present invention provides compounds of formulae (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidic mimetics that inhibit the protease 3CL of coronavirus and are useful in the treatment of conditions caused by viral infections, including COVID-19.
Absstract of: CN122279105A
The invention discloses an RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification) virus nucleic acid semi-quantitative detection method and a kit based on subpackaged freeze-dried microspheres and a multi-channel micro-fluidic chip. The method comprises the following steps: designing two sets of independent LAMP primer groups P1 and P2 aiming at an SARS-CoV-2 Omicro strain N gene, a Zika virus NS5 gene, an H1N1 influenza virus M1 gene and an H3N2 influenza virus NP gene respectively; the method comprises the following steps: independently mixing an RT-LAMP premixed solution containing components such as Bst DNA polymerase and an LAMP primer mixed solution with a freeze-drying protective agent respectively to prepare two types of freeze-dried microspheres which are independent from each other; the N-channel micro-fluidic chip is used for carrying out gradient dilution and parallel RT-LAMP amplification on the same sample, and the concentration of viral nucleic acid in the sample is judged through positive and negative turning points of each channel. The method is simple and convenient to operate, does not need equipment such as a fluorescent quantitative PCR instrument in the whole process, and is suitable for rapid detection of viruses in different scenes.
Absstract of: AU2026204379A1
The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2. 5 un u n
Absstract of: US20260174873A1
Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and/or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly effective for catalyzing anti-viral RNase properties. In various embodiments compositions of cationized nucleases in combination with a dendrimer demonstrated this synergistic amplification of anti-viral effectiveness and are used in pharmaceutically effective dosages as therapeutics against covid-19 and a broad spectrum of viruses. An exemplar formulation which exhibits a positive dendrimer effect is cationized RNase A mixed and/or complexed with gen 2 PAMAM dendrimer.
Absstract of: AU2026204287A1
The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. un u n
Absstract of: WO2023209177A1
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.
Absstract of: US20260177549A1
0000 Provided herein are methods, diagnostic instruments, and kits for detecting the presence or absence of an analyte associated with a disease in a subject. In some embodiments, the disease is Lyme disease, SARS-CoV-2, or a human immunodeficiency virus infection.
Absstract of: US20260176302A1
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.
Absstract of: WO2026133815A1
This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and/or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and/or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.
Absstract of: WO2026133305A2
A nanobody-based point-of-care lateral flow immunoassay (LFA) for the rapid, cost-effective detection of SARS-CoV-2 and MERS-CoV proteins in biological samples is disclosed. The assay described herein uses nanobody-based binding agents that selectively capture and detect viral antigens, such as spike (S) proteins and receptor-binding domains (RBDs), with high sensitivity and specificity. The LFA utilizes a colorimetric readout visible to the naked eye, eliminating the need for specialized equipment. The assay supports single and multiplex detection formats, enabling simultaneous analysis of multiple viral analytes. The LFAs are stable under standard storage conditions and provide a practical solution for decentralized and scalable testing.
Absstract of: WO2026131760A1
The present invention relates notably to specific single-domain antibodies (sdAbs) targeting RNA-dependent RNA polymerase (RdRp) activity and their use in the prevention and/or treatment of a virus infection from Coronaviruses, and more particularly of SARS-CoV-2.
Absstract of: WO2026132293A1
Advantageous specific symmetric diaryl hydantoin compounds are provided that have surprising activity as protease inhibitors against the main protease of coronavirus (MPRO), and thus can be used to treat a host in need thereof with a coronavirus including the SARS CoV-2 virus or a seasonal coronavirus in a host.
Absstract of: KR20260095805A
본 발명은 사스 코로나 바이러스 2 변이체의 스파이크 단백질에 특이적인 결합 분자 및 이의 용도에 관한 것이다. 보다 구체적으로는, 본 발명의 결합 분자는 사스 코로나 바이러스 2(SARS-CoV-2) 변이체의 스파이크 단백질(Spike protein)의 RBD(Receptor binding domain) 영역에 특이적인 결합 능력을 가지고, 사스 코로나 바이러스 감염증에 대한 치료제와 비교하여 우수한 중화 활성을 나타냄을 확인하였는 바, 사스 코로나 바이러스 감염증에 대한 예방 또는 치료에 활용될 수 있다.
Absstract of: EP4763985A1
The present invention concerns the creation of antisense oligonucleotides (ASOs) with no cytotoxicity that are very active as therapeutic agents in knocking down the replication of SARS-CoV-2 in human cells with pan activity against all known past and current variants.
Nº publicación: EP4763857A2 24/06/2026
Applicant:
PASTEUR INSTITUT [FR]
Institut Pasteur
Absstract of: EP4763857A2
0001 The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
BOPI
Electronic site
